These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
113 related items for PubMed ID: 8591853
1. The role of hepatobiliary scintigraphy in cystic fibrosis. O'Connor PJ, Southern KW, Bowler IM, Irving HC, Robinson PJ, Littlewood JM. Hepatology; 1996 Feb; 23(2):281-7. PubMed ID: 8591853 [Abstract] [Full Text] [Related]
2. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Hepatology; 1992 Apr; 15(4):677-84. PubMed ID: 1551646 [Abstract] [Full Text] [Related]
3. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. Nousia-Arvanitakis S, Fotoulaki M, Economou H, Xefteri M, Galli-Tsinopoulou A. J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276 [Abstract] [Full Text] [Related]
4. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease. Colombo C, Crosignani A, Battezzati PM, Castellani MR, Comi S, Melzi ML, Giunta A. J Hepatol; 1999 Oct; 31(4):672-7. PubMed ID: 10551391 [Abstract] [Full Text] [Related]
7. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168 [Abstract] [Full Text] [Related]
9. Liver disease and common-bile-duct stenosis in cystic fibrosis. Gaskin KJ, Waters DL, Howman-Giles R, de Silva M, Earl JW, Martin HC, Kan AE, Brown JM, Dorney SF. N Engl J Med; 1988 Feb 11; 318(6):340-6. PubMed ID: 3340104 [Abstract] [Full Text] [Related]
10. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK. Liver Int; 2007 Dec 11; 27(10):1402-8. PubMed ID: 18036103 [Abstract] [Full Text] [Related]
16. The role of IDA scintigraphy in the follow-up of liver disease in patients with cystic fibrosis. Foster JA, Ramsden WH, Conway SP, Taylor JM, Etherington C. Nucl Med Commun; 2002 Jul 11; 23(7):673-81. PubMed ID: 12089490 [Abstract] [Full Text] [Related]
18. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Siano M, De Gregorio F, Boggia B, Sepe A, Ferri P, Buonpensiero P, Di Pasqua A, Raia V. Dig Liver Dis; 2010 Jun 11; 42(6):428-31. PubMed ID: 20034860 [Abstract] [Full Text] [Related]
19. Sonographic findings of the hepatobiliary-pancreatic system in adult patients with cystic fibrosis. Dietrich CF, Chichakli M, Hirche TO, Bargon J, Leitzmann P, Wagner TO, Lembcke B. J Ultrasound Med; 2002 Apr 11; 21(4):409-16; quiz 417. PubMed ID: 11934098 [Abstract] [Full Text] [Related]
20. [Hepatobiliary scintigraphy in the study of neonatal hepatic cholestasis]. Salvatori M, Valenza V, De Franco A, De Gaetano AM. Radiol Med; 1989 Dec 11; 78(6):638-44. PubMed ID: 2516635 [Abstract] [Full Text] [Related] Page: [Next] [New Search]